Skip to main content
Delfa

← All trials/NCT07190144

Completed

Coronary Flow Reserve Changes After Semaglutide Treatment

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

122

Study population

Diabetes (other / unspecified), Obesity / overweight

Eligibility highlights

-

Primary endpoint

•Number of patients who had acute coronary syndrome

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07190144
Org study IDIstanbulU-EBKaraayvaz-2

Timeline

Milestones

Study start2025-01-07actual
Primary completion2025-08-01actual
Study completion2025-08-01actual
Study first posted2025-09-24actual
Last update posted2025-09-24actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Diabetes (other / unspecified)Obesity / overweight

Who can enroll

Minimum age28 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted
Sampling methodProbability sample

Study population text

Patients who were diabetic and non-diabetic and planned to start semaglutide has referred to cardiology clinic for the study.

Inclusion criteria

•Patients who were planned to start semaglutide.

Exclusion criteria

•Ischemic heart disease
•Previous stent implantation or coronary bypass
•Heart failure
•Cardiomyopathies
•Inflammatory diseases
•Autoimmune rheumatic disease
•Chronic liver and renal insufficiency

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes
1
Weight & body composition
1

Cardiovascular outcomes

1 endpoint
Primary/protocol endpoint

Number of patients who had acute coronary syndrome

Time frame:From start of the study to 3 months after

event count, event

Weight & body composition

1 endpoint
Secondary/protocol endpoint/low confidence

Number of patients who can not lose weight

Time frame:From start to 3 months

threshold achievement, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.